ROG — Roche Holding AG Share Price
Last trade - 00:00- CH₣203.30bn
- CH₣226.74bn
- CH₣60.50bn
- 88
- 36
- 87
- 85
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.17 | ||
| PEG Ratio (f) | 0.98 | ||
| EPS Growth (f) | 14.17% | ||
| Dividend Yield (f) | 3.94% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.4 | ||
| Price to Tang. Book | 30.86 | ||
| Price to Free Cashflow | 13.48 | ||
| Price to Sales | 3.36 | ||
| EV to EBITDA | 13.6 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 17.72% | ||
| Return on Equity | 27.1% | ||
| Operating Margin | 21.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 58,323 | 62,801 | 63,281 | 58,716 | 60,495 | 64,727.98 | 67,408.61 | -0.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -7.28 | -2.16 | +7.73 | +0.65 | -3.05 | +18.16 | +6.26 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Directors
- Christoph Franz NEC (61)
- Severin Schwan CEO (55)
- Andre Hoffmann NVC (64)
- Alan Hippe CFO (55)
- Cristina Wilbur CHO (55)
- Pascale Schmidt CCO (49)
- Claudia Boeckstiegel GCN (58)
- William Anderson EXB (54)
- William Pao EXB (55)
- Aviv Regev EXB (51)
- James Sabry EXB (62)
- Barbara Schaedler EXB (60)
- Thomas Schinecker EXB (47)
- Per-Olof Attinger SEC (62)
- Annette Luther SEC (52)
- Julie Brown NID (60)
- Paul Bulcke NID (68)
- Hans Clevers NID (65)
- Joerg Duschmale NID (38)
- Patrick Frost NID (54)
- Anita Hauser NID (53)
- Richard Lifton NID (69)
- Bernard Poussot NID (70)
- Claudia Suessmuth Dyckerhoff NID (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 13th, 1966
- Public Since
- May 4th, 2001
- No. of Employees
- 103,249
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 795,400,695
- Address
- Grenzacherstrasse 124, BASEL, 4002
- Web
- https://www.roche.com/
- Phone
- +41 9732354295
- Contact
- Loren Kalm
- Auditors
- KPMG AG
Latest News for ROG
Upcoming Events for ROG
Roche Holding AG at UBS Best of Europe Virtual One-on-One Conference
Roche Holding AG at Berenberg Diagnostics Conference
Roche Holding AG at Bank of America Global Healthcare Conference
Roche Holding AG Diagnostics Day
Roche Holding AG at Bernstein Strategic Decisions Conference
Roche Holding AG at BNP Paribas Exane CEO Conference
Roche Holding AG at Jefferies Global Life Science Conference
Roche Holding AG at Barclays Conversations with the C-Suite
Roche Holding AG at Goldman Sachs Global Healthcare Conference
Roche Holding AG at Kepler Cheuvreux Virtual CEO/CFO Tour
Roche Holding AG at Citi European Healthcare Conference
Roche Holding AG at JPMorgan European Healthcare Forum
Half Year 2025 Roche Holding AG Earnings Release
Half Year 2025 Roche Holding AG Earnings Call
Roche Holding AG at UBS Precision Medicine Frontiers Summit
Roche Holding AG at Morgan Stanley Global Healthcare Conference
Roche Holding AG at Nephron Napa Summit
Roche Holding AG Pharma Day
Roche Holding AG at Bank of America Global Healthcare Conference
Roche Holding AG at JPMorgan CEO Conference Call Series
Similar to ROG
Cosmo Pharmaceuticals NV
SIX Swiss Exchange
Curatis Holding AG
SIX Swiss Exchange
Dottikon Es Holding AG
SIX Swiss Exchange
Galenica AG
SIX Swiss Exchange
Novartis AG
SIX Swiss Exchange
FAQ
As of Today at 22:57 UTC, shares in Roche Holding AG are trading at CH₣255.60. This share price information is delayed by 15 minutes.
Shares in Roche Holding AG last closed at CH₣255.60 and the price had moved by +16.13% over the past 365 days. In terms of relative price strength the Roche Holding AG share price has outperformed the FTSE Global All Cap Index by +14.08% over the past year.
The overall consensus recommendation for Roche Holding AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Roche Holding AG dividend yield is 3.79% based on the trailing twelve month period.
Last year, Roche Holding AG paid a total dividend of CH₣9.70, and it currently has a trailing dividend yield of 3.79%. We do not have any data on when Roche Holding AG is to next pay dividends.
We do not have data on when Roche Holding AG is to next pay dividends. The historic dividend yield on Roche Holding AG shares is currently 3.79%.
To buy shares in Roche Holding AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣255.60, shares in Roche Holding AG had a market capitalisation of CH₣203.30bn.
Here are the trading details for Roche Holding AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: ROG
Based on an overall assessment of its quality, value and momentum Roche Holding AG is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Roche Holding AG is CH₣309.93. That is 21.26% above the last closing price of CH₣255.60.
Analysts covering Roche Holding AG currently have a consensus Earnings Per Share (EPS) forecast of CH₣20.61 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Roche Holding AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -4.07%.
As of the last closing price of CH₣255.60, shares in Roche Holding AG were trading -6.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Roche Holding AG PE ratio based on its reported earnings over the past 12 months is 12.17. The shares last closed at CH₣255.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Roche Holding AG's management team is headed by:
- Christoph Franz - NEC
- Severin Schwan - CEO
- Andre Hoffmann - NVC
- Alan Hippe - CFO
- Cristina Wilbur - CHO
- Pascale Schmidt - CCO
- Claudia Boeckstiegel - GCN
- William Anderson - EXB
- William Pao - EXB
- Aviv Regev - EXB
- James Sabry - EXB
- Barbara Schaedler - EXB
- Thomas Schinecker - EXB
- Per-Olof Attinger - SEC
- Annette Luther - SEC
- Julie Brown - NID
- Paul Bulcke - NID
- Hans Clevers - NID
- Joerg Duschmale - NID
- Patrick Frost - NID
- Anita Hauser - NID
- Richard Lifton - NID
- Bernard Poussot - NID
- Claudia Suessmuth Dyckerhoff - NID